Incentives for innovation: Neglected diseases

  • Mary Moran
Part of the Economía de la Salud y Gestión Sanitaria book series (SESGS)


Incentives to stimulate greater industry pharmaceutical innovation are in place in most OECD countries. However, they are never more needed than for so-called “neglected diseases” (NDs). These are diseases such as malaria, tuberculosis and helminth infections that afflict hundreds of millions of poor patients in developing countries. We focus here on how to stimulate industry innovation for these diseases, and on the circums tances in which alternative routes of innovation will be needed.


Malaria Vaccine Buruli Ulcer Small Business Innovation Research Market Exclusivity Price Subsidy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    The Global Fund to Fight AIDS, TB and Malaria (GFATM): Introduction to the Affordable Medicines Facility — malaria. Available at: pdf (accessed 8 November 2010).Google Scholar
  2. 2.
    Hollis A, Pogge T, et al. The Health Impact Fund: Pay-for-Performance (WHO Expert Working Group Submission 2009). Available at: (accessed 8 November 2010).Google Scholar
  3. 3.
    Light D. Advanced Market Commitments: Current Realities and Alternate Approaches: HAI Paper Series. 2009. Available at: 20Realities%20&%20Alternate%20Approaches%20FINAL.pdf (Accessed 8 November 2010).Google Scholar
  4. 4.
    IHP — Taskforce on Innovative Financing for Health Systems: Raising and Channeling Funds. Working Group 2 report (2009). Available at: 090817%20WORKING_GROUP_2(1).pdf (accessed 8 November 2010).Google Scholar
  5. 5.
    IAVI (2009). Financing the Accelerated Development of Vaccines for AIDS, TB, and Malaria: Design of the PDP Financing Facility and an Analysis of Its Feasibility (a Report to Aeras, IAVI, and MVI). Available at: 20vaccines%20for%20AIDS,%20TB,%20and%20malaria.pdf (accessed 8 November 2010).Google Scholar
  6. 6.
    Grabowski H, Ridley D, Moe J. Priority Review Vouchers to encourage innovation for neglected diseases. 2008. Available at: (accessed 8 November 2010).Google Scholar
  7. 7.
    Ridley DB, Grabowski HG, Moe JL. Developing drugs for developing countries. Health Affairs. 2006, 25:313–324.PubMedCrossRefGoogle Scholar
  8. 8.
    Novartis media release. September 15, 2008. Available at: en/2008/1251164.shtml. Accessed 2 November 2010Google Scholar
  9. 9.
    Di Masi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. Journal of Health Economics. 2003;22:151–185.CrossRefGoogle Scholar
  10. 10.
    UNITAID. Proposals for New and Innovative Sources of Funding Medicines Patent Pool. 2009. Availa ble at: (accessed 8 November 2010).Google Scholar
  11. 11.
    IFPMA Submission to the Public Hearing on Proposals for R&D Financing. Available at: (accessed 8 November 2010).Google Scholar
  12. 12.
    Everts S. Open-Source Science — Online research communities aim to unite scientists worldwide to find cures for neglected diseases. Chemical and Engineering News. 2006; 84(30):34–35. Available at: (accessed 8 November 2010).CrossRefGoogle Scholar
  13. 13.
    Pelfrene E. Article 58: A route to scientific opinion. EMEA; 2008. Available at: http://www.kaisernetwork. org/health_cast/uploaded_files/Article_58_A_Route_to_Scientific_Adoption_Eric_ Pelfrene_5.6.08%5B1%5D.pdf (accessed 8 November 2010).Google Scholar
  14. 14.
    Moran M, Guzman J, Ropars AL, Illmer A. The role of Product Development Partnerships in research and development for neglected diseases. International Health. 2010;2(2). Available at: (accessed 8 November 2010).Google Scholar
  15. 15.
    Health Action International (HAI). Response to the Expert Working Group on Alternative Finan — cing. 2009. Available at: (accessed 8 November 2010).Google Scholar
  16. 16.
    Celgene media release, January 27, 2005. Available at: 111960&p=irol-newsArticle_Print&ID=667281&highlight=.(Accessed 2 November 2010).Google Scholar

Copyright information

© Springer Healthcare Ibérica SL. 2011

Authors and Affiliations

  • Mary Moran

There are no affiliations available

Personalised recommendations